There is significant research ongoing in Immuno-Oncology around the world. Bristol-Myers Squibb has an extensive research program with several I-O agents across multiple tumor types. Evidence of tumor-mediated inhibition of the immune system has been observed in the following advanced cancers.38-59
Keep learning what is possible in this rapidly evolving field.
© 2013 Bristol-Myers Squibb Company
ONCUS13UB03085-01-01 ONCHQ13NP07822-0 12/13